Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.

Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer (2008) 15.20

Molecular mechanisms and clinical applications of angiogenesis. Nature (2011) 13.36

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell (2007) 12.52

Tumor angiogenesis. N Engl J Med (2008) 11.30

Imaging in the era of molecular oncology. Nature (2008) 11.10

A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med (2014) 9.19

Hypoxia and inflammation. N Engl J Med (2011) 7.71

Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol (2010) 7.26

Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest (2006) 6.12

Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell (2009) 5.91

Going deeper than microscopy: the optical imaging frontier in biology. Nat Methods (2010) 5.65

Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev (2011) 5.64

Three-dimensional microscopy of the tumor microenvironment in vivo using optical frequency domain imaging. Nat Med (2009) 5.41

Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat Nanotechnol (2012) 4.84

Influence of tumour micro-environment heterogeneity on therapeutic response. Nature (2013) 4.78

Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell (2006) 4.55

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol (2009) 4.54

Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell (2008) 4.51

Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol (2013) 4.23

Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol (2009) 4.17

Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med (2009) 3.85

Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol (2008) 3.84

A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature (2008) 3.74

Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol (2010) 3.67

Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc Res (2007) 3.64

Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors. Nat Rev Cancer (2010) 3.48

Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci U S A (2011) 3.48

Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res (2007) 3.45

Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev (2012) 3.44

Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol (2010) 3.43

Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol (2009) 3.39

Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut (2012) 3.13

Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol (2009) 3.02

A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res (2009) 3.00

Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer (2010) 2.93

Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell (2014) 2.71

Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. Proc Natl Acad Sci U S A (2012) 2.66

miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells. Cancer Cell (2008) 2.57

Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res (2010) 2.57

Pericytes limit tumor cell metastasis. J Clin Invest (2006) 2.55

Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models. Microcirculation (2010) 2.53

Coregulation of vascular tube stabilization by endothelial cell TIMP-2 and pericyte TIMP-3. J Cell Biol (2006) 2.50

Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A (2012) 2.50

Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med (2008) 2.40

Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. Nat Immunol (2015) 2.32

Bone tissue engineering: recent advances and challenges. Crit Rev Biomed Eng (2012) 2.27

Endothelial podosome rosettes regulate vascular branching in tumour angiogenesis. Nat Cell Biol (2014) 2.22

Pulsed-high intensity focused ultrasound and low temperature-sensitive liposomes for enhanced targeted drug delivery and antitumor effect. Clin Cancer Res (2007) 2.17

The biology of brain metastases-translation to new therapies. Nat Rev Clin Oncol (2011) 2.16

Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev (2008) 2.16

Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis (2009) 2.15

Adipose tissue angiogenesis as a therapeutic target for obesity and metabolic diseases. Nat Rev Drug Discov (2010) 2.14

Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci U S A (2013) 2.14

HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol (2011) 2.10

Fluid forces control endothelial sprouting. Proc Natl Acad Sci U S A (2011) 2.09

Biology of hypoxia-inducible factor-2alpha in development and disease. Cell Death Differ (2008) 2.08

Mathematical model identifies blood biomarker-based early cancer detection strategies and limitations. Sci Transl Med (2011) 2.07

Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis (2014) 2.07

Prospective study of prostate tumor angiogenesis and cancer-specific mortality in the health professionals follow-up study. J Clin Oncol (2009) 2.01

Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst (2011) 1.98

Intraventricular hemorrhage in premature infants: mechanism of disease. Pediatr Res (2010) 1.98

The shunt problem: control of functional shunting in normal and tumour vasculature. Nat Rev Cancer (2010) 1.97

Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype. Neuro Oncol (2012) 1.96

Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther (2008) 1.96

Macrophages and therapeutic resistance in cancer. Cancer Cell (2015) 1.95

Ultrasound mediated delivery of drugs and genes to solid tumors. Adv Drug Deliv Rev (2008) 1.93

Hypoxia, inflammation, and the tumor microenvironment in metastatic disease. Cancer Metastasis Rev (2010) 1.92

Dissecting cancer through mathematics: from the cell to the animal model. Nat Rev Cancer (2010) 1.92

Micro-environmental mechanical stress controls tumor spheroid size and morphology by suppressing proliferation and inducing apoptosis in cancer cells. PLoS One (2009) 1.92

Tumor radiation response enhancement by acoustical stimulation of the vasculature. Proc Natl Acad Sci U S A (2012) 1.90

Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res (2010) 1.90

Active versus passive mechanisms in metastasis: do cancer cells crawl into vessels, or are they pushed? Lancet Oncol (2007) 1.89

Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels. Am J Pathol (2009) 1.87

Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol (2010) 1.86

Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy. Expert Opin Biol Ther (2008) 1.84

Combining two strategies to improve perfusion and drug delivery in solid tumors. Proc Natl Acad Sci U S A (2013) 1.83

Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro Oncol (2009) 1.83

Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102. Cancer Res (2007) 1.83

Pulsed high-intensity focused ultrasound enhances apoptosis and growth inhibition of squamous cell carcinoma xenografts with proteasome inhibitor bortezomib. Radiology (2008) 1.82

Anticancer strategies involving the vasculature. Nat Rev Clin Oncol (2009) 1.82

Controlling escape from angiogenesis inhibitors. Nat Rev Cancer (2012) 1.81

Hypoxia-induced pathological angiogenesis mediates tumor cell dissemination, invasion, and metastasis in a zebrafish tumor model. Proc Natl Acad Sci U S A (2009) 1.81

Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. BMC Cancer (2009) 1.80

Selective killing of tumor neovasculature paradoxically improves chemotherapy delivery to tumors. Cancer Res (2010) 1.80

Residual breast cancer diagnosed by MRI in patients receiving neoadjuvant chemotherapy with and without bevacizumab. Ann Surg Oncol (2009) 1.80

Imaging angiogenesis and the microenvironment. APMIS (2008) 1.77

Tumour vascularization: sprouting angiogenesis and beyond. Cancer Metastasis Rev (2007) 1.76

Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res (2013) 1.73

Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies. Proc Natl Acad Sci U S A (2007) 1.73

Spatial and temporal role of the apelin/APJ system in the caliber size regulation of blood vessels during angiogenesis. EMBO J (2008) 1.72

Elusive identities and overlapping phenotypes of proangiogenic myeloid cells in tumors. Am J Pathol (2010) 1.70

New treatments for neovascular acute macular degeneration. BMJ (2007) 1.69

Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood (2006) 1.69

Effects of vascular-endothelial protein tyrosine phosphatase inhibition on breast cancer vasculature and metastatic progression. J Natl Cancer Inst (2013) 1.69

Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol Cancer Ther (2009) 1.67

Fibronectins in vascular morphogenesis. Angiogenesis (2009) 1.66

Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease. Cold Spring Harb Perspect Med (2012) 1.66

Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end? Nat Rev Clin Oncol (2012) 1.65

Biological barriers to therapy with antisense and siRNA oligonucleotides. Mol Pharm (2009) 1.65

Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial. Urology (2010) 1.65